Navigation Links
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
Date:4/13/2011

NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.

The $3 million federal grant was awarded to three University of California, Davis (UCD) researchers: Randi Hagerman, M.D., an international authority on Fragile X-related disorders; Michael Rogawski, M.D., Ph.D., a world-renowned epilepsy researcher; and David Hessl, Ph.D., an expert in psychophysiology studies. The group will enroll 60 children between the ages of six and 17 years to study the safety and effectiveness of ganaxolone for treating behaviors and anxiety common with FXS.

"The fact that a study with ganaxolone was awarded this grant is a testament to the potential for neurosteroid augmentation as a new treatment for FXS patients," stated Gail Farfel, Ph.D., Chief Clinicaland Regulatory Officer of Marinus. "The scientific data suggests that ganaxolone may be ideally suited to reverse FXS symptoms related to the down-regulation of the neurosteroid binding site on GABA-A ion channels."

"Over the next few months, we will work with UCD to provide ganaxolone for the FXS study and work on obtaining regulatory approval from the Food and Drug Administration to allow the researchers to conduct this study under Marinus' Investigational New Drug Application," commented Kenneth Shaw, Ph.D., Senior Vice President, R&D at Marinus.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolon
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Marinus Pharmaceuticals Issued Patent for Ganaxolone
2. Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
3. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
4. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
5. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
6. Webcast and Conference Call Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
7. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
8. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
9. Idenix Pharmaceuticals Prices Public Offering of Common Stock
10. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
(Date:6/30/2015)... 2015  Marken, the leading clinical trial logistics organization ... has been granted permission by the government to deliver ... product in Korea.  This precedent-setting shipment has allowed several ... continue receiving their clinical trial drugs during the outbreak ... emergency was caused by recent partial closures of medical ...
(Date:6/30/2015)... PharmaVentures is pleased to announce ... Oy (CMT) on its divestment of certain assets to ... world leading capabilities in cellular imaging and analysis. ... of successful global deals in the life science research ... Walton , CEO, PharmaVentures, commented: "PharmaVentures is delighted to ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
... WORTH, Texas, Aug. 26 Healthpoint today announced,that ... the effectiveness of a,widely prescribed enzymatic debriding agent ... study was prompted, in part, by clinical reports,of ... healing,properties associated with Collagenase SANTYL(R) Ointment.(1,2), "Given ...
... Inc.,(Nasdaq: XTNT ) today announced that the positive ... in the most recent issue of the,peer-reviewed journal, EuroIntervention. ... Stella, M.D., of University Medical Center Utrecht, Utrecht,The Netherlands ... clinical,sites across Europe., The one-year CUSTOM II trial, ...
Cached Medicine Technology:Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
(Date:6/30/2015)... , ... June 30, 2015 , ... On June 26, ... Acne ,” listed five triggers that most people would not expect to cause ... and toothpaste. The primary causes of acne are clogged pores and bacteria ...
(Date:6/30/2015)... York (PRWEB) , ... June 30, 2015 , ... ... http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in the ... convenes its next monthly Status Conference. According to the Court’s calendar, that conference ...
(Date:6/30/2015)... ... June 30, 2015 , ... The U.S. Women's National Soccer Team will face the ... match will be on Sunday, August 16th at Heinz Field in Pittsburgh at 1:30 p.m. ... at Finley Stadium in Chattanooga, TN. , The USA WNT previously played at Heinz Field ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion piece ... fat transfer procedures had over breast implants when reconstructing breasts after a mastectomy. ... “look and feel natural,” have increased sensation, and are less likely than implant ...
(Date:6/30/2015)... ... June 30, 2015 , ... LifeAID Beverage Company ... two leading organizations dedicated to raising worldwide awareness of the burgeoning “adaptive” movement, ... is now the official charity of FitAID. I AM ADAPTIVE is a non-profit ...
Breaking Medicine News(10 mins):Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:LifeAID Beverage Company Partners With The Adaptive Movement 2Health News:LifeAID Beverage Company Partners With The Adaptive Movement 3
... Bouts of heavy drinking can increase male teens, levels of ... drinking, a new study finds. The study included more ... from first-grade until they were 20 years old, with another ... teens, boys with moderate levels of impulsive behavior showed a ...
... National Institutes of Health (NIH), National Institute of Allergy ... Center up to $52.8 million over the next seven ... external quality assurance programs that monitor laboratories involved ... The project, External Quality Assurance Oversight Laboratory ...
... HealthDay Reporter , TUESDAY, Nov. 16 (HealthDay News) -- By ... able to partially restore the heart,s ability to pump in ... first time gene therapy has been tested and shown to ... author Dr. Donna Mancini, professor of medicine and the Sudhir ...
... a prescription filled can undermine medical treatment, result in ... for the patient. An editorial in the Nov. 16 ... highlights the problem and issues a call to action. ... Medication Nonadherence," Michael D. Murray, PharmD, MPH, a Regenstrief ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... that,s little comfort for those involved: Sometimes surgical instruments and ... from Johns Hopkins University. Children suffering from such mishaps ... in hospital stays that are more than twice as long ...
... get most of their sleep at night (as opposed to during ... children who don,t sleep as much at night. That,s the ... University of Montreal and the University of Minnesota. The research appears ... . The study, of 60 Canadian children at ages 1, ...
Cached Medicine News:Health News:For Teen Boys, Heavy Drinking & Impulsivity May Be Vicious Circle 2Health News:Duke to lead oversight of HIV laboratories worldwide 2Health News:Duke to lead oversight of HIV laboratories worldwide 3Health News:Gene Therapy Shows Potential Against Heart Failure 2Health News:Not following doctor's orders: Prescription abandonment 2Health News:Sponges, Surgical Tools Sometimes Left in Kids After Operation 2Health News:Sponges, Surgical Tools Sometimes Left in Kids After Operation 3Health News:Nighttime sleep found beneficial to infants' skills 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: